Browsing: Lilly

By Maggie Fick and Patrick Wingrove LONDON/NEW YORK (Reuters) – As Eli Lilly (NYSE:)’s weight-loss drug Zepbound gains ground in…

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a…

(Reuters) – U.S. drugmaker Eli Lilly (NYSE:) expects its blockbuster weight-loss drug to officially come out of shortage in the…

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time…

We’re increasing our price targets on a handful of positions that have recently made new all-time highs and another that…

LONDON (Reuters) – Shares in Novo Nordisk (NYSE:), maker of the wildly popular obesity drug Wegovy, were down 1.9% on…

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a…

By Patrick Wingrove (Reuters) – Eli Lilly (NYSE:) on Friday said its popular weight-loss drug Zepbound helped resolve moderate to…

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time…

By Patrick Wingrove (Reuters) -Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana…